Abstract Perpetuation of immune deficiency throughout tumor development is, to a great degree, the result of impairment of dendritic cell function by products secreted by tumors. They include cytokines, non-tumor-specific molecules (gangliosides, prostanoids, nitric oxide, etc.) and tumor-(specific) antigens (MUC-1, PSA, Her-2 neu). They may engender a distortion of dendritic cell development, block dendritic cell maturation, induce dendritic cell apoptosis or interfere with antigen presentation. Identifying those molecules and their interaction with dendritic cells will accelerate the development of more efficient immunotherapies. In this chapter we review the current literature on these interactions and highlight the possible avenues of minimization of their deleterious effects.
Introduction
The induction of an effective immunological response against tumors is mainly dependent on the effector cells of the innate and adaptive immunity with DC playing a very important regulatory role. Therefore, the context in which tumor antigens are presented to the immune system dictates the efficacy of tumoricidal responses. The spontaneous remission observed in a number of human cancers suggests that the immune system has the potential to present antigens adequately and thus eliminate malignant cells (Bodey 2002) . However, tumors usually evade immune clearance due to a number of mechanisms including recruitment of regulatory cell types (Pekarek et al. 1995; Vence et al. 2007 ), deletion of effector cells (Staveley-O'Carroll et al. 1998; Saito et al. 2000) or secretion of immunosuppressive factors (Gabrilovich 2004) . Here, we examine evidence on the role of tumor-derived factors inducing DC dysfunction and particularly the alteration of DC differentiation, maturation and longevity as a mechanism for immune suppression.
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Cytokines and Growth Factors Affecting Dendritic Cell Differentiation
One of the first cytokines reported to have an inhibitory effect on DC function in cancer was IL-10. This is a suppressive cytokine which exerts primarily antiinflammatory functions and antagonizes several functions of antigen-presenting cells (APC), including DC. It has been shown to inhibit the ability of DC to stimulate T cells, inducing antigen-specific anergy (Steinbrink et al. 1999) . IL-10 release has been reported from tumors like melanoma, multiple myeloma and lung cancer (Kruger-Krasagakes et al. 1994; Smith et al. 1994; Gu et al. 1996) as well as tumor-infiltrating macrophages, lymphocytes and peripheral blood lymphocytes (Kim et al. 1995; Asselin-Paturel et al. 1998 ). Importantly, IL-10 has been shown to prevent the differentiation of monocytes to DC (Allavena et al. 1998) as well as inhibit the antigen-presenting function of DC (Enk et al. 1993; Buelens et al. 1997 ). In addition, increased serum levels of IL-10 correlate with numerical deficiency and immature phenotype of circulating DC subsets in patients with hepatocellular carcinoma (Beckebaum et al. 2004) , indicating a clear association between tumor-related production of IL-10 and defects in DC differentiation . Secretion of IL-6 and M-CSF from carcinoma cells has also been observed to inhibit the differentiation of DC from CD34 + myeloid progenitors (MenetrierCaux et al. 1998 ). The molecular mechanisms responsible for this effect involve the modulation of GM-CSF and M-CSF receptor expression by tumor-secreted IL-6 and M-CSF (Menetrier-Caux et al. 1998 ). In addition, high levels of IL-6 have been correlated with poor prognosis in patients with multiple myeloma, renal cell carcinoma, melanoma and colorectal cancer (Blay et al. 1992; Deehan et al. 1994; Tartour et al. 1996; Ratta et al. 2002) . Tumor overproduction of IL-6 has been demonstrated to inhibit the colony growth of DC progenitors (Ratta et al. 2002) and sera from bone marrow of multiple myeloma patients (containing high levels of IL-6) have been shown to inhibit the induction of fully functional DC (Hayashi et al. 2003) . Another study has demonstrated that IL-6 plays a crucial role in maintaining an immature phenotype on DC in vivo (Park et al. 2004) , confirming the significant role of IL-6 in the inhibition of DC differentiation both in vitro and in vivo.
Granulocyte/monocyte-colony-stimulating factor (GM-CSF) has also been associated with tumor-induced dysfunction of myelopoiesis. Spontaneous production of GM-CSF has been reported for several types of human tumor cell lines (Bronte et al. 2000) and production of this cytokine has been associated with the ability of cancer cells to metastasize (Tsuchiya et al. 1988) . Although cancer cells modified to produce GM-CSF elicit robust antitumor immune responses by recruiting DC, the aberrant secretion of GM-CSF by some tumors could be deleterious to the host immune response. In mice, chronic GM-CSF production by tumors has been reported to suppress tumor-specific CTL responses through the generation of a population of inhibitory immature
Although these immature cells could be generated by the administration of GM-CSF alone, GM-CSF in combination with IL-4 induced their differentiation into mature APC (Bronte et al. 1999) underscoring the necessity of an appropriate cytokine milieu for adequate APC differentiation. Similarly, the production of large amounts of GM-CSF by some tumors could impair the immune response. This has been demonstrated in a study whereby vaccination with tumor cells producing large quantities of GM-CSF resulted in substantial accumulation of immature cells and immunosuppression in vivo (Serafini et al. 2004) . The relevance of these findings in humans has been confirmed with reports indicating that immune suppression and increased recurrence and metastasis in patients with head and neck squamous cell carcinoma were related to the presence of immature cells that secreted GM-CSF (Pak et al. 1995; Young et al. 1997) . Interestingly, these cells could be differentiated into fully functional DC in vitro, following culture with the pro-differentiating factor 1,25-dihydroxyvitamin D3 (Garrity et al. 1997) .
VEGF is another tumor-derived factor shown to affect differentiation of DC. VEGF is produced by different types of tumors and increased levels of this cytokine have been associated with poor prognosis in cancer (Toi et al. 1996) . VEGF plays a role in inducing proliferation of endothelial cells and formation of neo-vasculature within the tumor. It has also been demonstrated that VEGF significantly affects the differentiation of multiple hematopoietic lineages in vivo, including DC (Gabrilovich et al. 1998) . The inhibitory effect of VEGF on DC differentiation has been confirmed and increased VEGF levels have been reported to correlate with reduced number of infiltrating and circulating DC in patients with different types of cancer (Saito et al. 1998; Lissoni et al. 2001; Takahashi et al. 2004 ). In addition to altered differentiation of DC, elevated levels of VEGF have been associated with an increased number of immature cells with immunosuppressive function in the circulation of patients with cancer (Almand et al. 2000) . Notably, these cells could be differentiated into mature DC in vitro, after culture with all-trans retinoic acid (Almand et al. 2001 ). More recently, inhibition of VEGF has shown to improve on DC maturation while yielding discreet improvement on immune responses (Fricke et al. 2007 ).
Other Immune Mediators Affecting Dendritic Cell Differentiation
Gangliosides (membrane-bound glycosphingolipids with a sialic acid moiety) could contribute to tumor-induced immune suppression by altering differentiation of several lineages and hematopoiesis (Sietsma et al. 1998) (Fig. 7 . 1 AQ1 ). A number of tumors including medulloblastoma, lymphoma, melanoma, neuroblastoma, retinoblastoma and hepatoma are known to display an aberrant ganglioside composition (Birkle et al. 2003 ) also shedding some of these molecules into the tumor milieu and the circulation (Ladisch et al. 1987; Portoukalian et al. 1993 ). More importantly, it has been shown that neuroblastoma and melanoma-derived gangliosides impair the phenotypic and functional differentiation of DC providing another mechanism for tumor-induced immunosuppression (Shurin et al. 2001; Peguet-Navarro et al. 2003) (Fig. 7 . 2 AQ2 ). It appears that gangliosides interfere with the expression of costimulatory molecules and inhibit NF-B (Caldwell et al. 2003) . Interestingly, some DC function might be corrected with IL-15 (Tourkova et al. 2005) .
There are other factors that could play redundant or synergistic roles on the inhibition of DC differentiation by tumors. Several reports now correlate alterations of arachidonic acid metabolism with carcinogenesis (Gately and Li 2004) . Arachidonic acid metabolites (prostanoids) including prostaglandins and thromboxanes are synthesized by cyclooxygenase (COX)-1 and -2. In several types of cancer, including melanoma, colon, breast and lung carcinoma, alterations in the expression of these enzymes have been reported (Tsujii et al. 1997; Denkert et al. 2001) . Most studies indicate that prostanoids have a role in tumorigenesis mostly through their pro-angiogenic effects (Gately and Li 2004 
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However, recent data indicate that prostanoids may also contribute to carcinogenesis through inhibition of DC differentiation. Indeed, it has recently been demonstrated that tumor COX-2 expression decreases host antitumor response by impairing DC maturation and activity (Sharma et al. 2003 ). This appears to be through specific signaling pathways. The EP2 receptor, one of the four receptors for prostaglandin E2 (PgE2), has been reported to mediate PgE2-induced inhibition of DC differentiation and function, playing an essential role in impaired antitumor responses . It has also been shown that COX-2-regulated prostanoids inhibit DC production of IL-12, increase secretion of IL-10 and contribute to tumor-induced inhibition of DC development (Sombroek et al. 2002) .
SPB Fig. 7 .2 Tumor-induced dendritic cell dysfunction generates ineffective immune responses. In the absence of tumor-derived factors, DC differentiate and mature appropriately. Mature DC increase their capacity to process antigens and express the cytokines and costimulatory molecules essential for initiating an effective immune response. Under the influence of tumor-derived factors, immature cells, immature DC and apoptotic DC are generated and accumulated. Although immature cells appear not to present antigens, they can suppress tumor-specific T-cell activation through the production of reactive oxygen species (ROS). Immature DC and apoptotic DC can present antigens but in the absence of adequate costimulation and cytokine secretion, they can induce anergy, abortive proliferation or induction of regulatory T cells, thus favouring tumor evasion
Tumor Antigens and Metabolites Affecting Dendritic Cell Differentiation
Various reports indicate that other factors produced by malignant cells like tumor antigens (MUC1 and PSA) or polyamines (spermine) are also responsible for impaired DC maturation and function (Aalamian et al. 2003; Della Bella et al. 2003; Monti et al. 2004 ). Interestingly, it has been demonstrated that whereas DC readily take up tumor antigens from epithelial tumors such as MUC1 and HER-2/neu, these glycoproteins inhibit their own transport to late endosomal compartments for processing and binding to class II MHC molecules (Hiltbold et al. 2000) . Similarly, prostate-specific antigen (PSA) clearly inhibited the DC differentiation and maturation of DC in vitro (Aalamian et al. 2003) . Although inhibition of DC maturation by serum from prostate cancer patients correlate with PSA levels (Aalamian-Matheis et al. 2007 ), the physiological significance of these findings has not been proven in vivo. Polyamines, in contrast, appear to play a relevant role in vivo. Putrescine, spermidine and spermine are essential for mammalian cell proliferation and differentiation. They have been implicated in impaired DC maturation and, more importantly, a significant negative correlation has been found between plasma levels of spermine and DC production of IL-12 in patients with breast cancer (Della Bella et al. 2003) . These molecules have also been implicated in the inhibition of T-cell activity by immature suppressive cells in vivo (Bronte et al. 2003) . Given that polyamines are nutrients constantly produced in the tumor microenvironment, these molecules could assist tumor evasion by supporting tumor growth and affect DC differentiation and T-cell function. Similarly, a product of the cleavage of surface death receptor 6 (DR6) overexpressed in tumors has been described to interfere with DC development (Derosa et al. 2008 ).
Implications of Altered Dendritic Cell Differentiation
DC precursors and immature DC gain access to peripheral blood en route to peripheral tissues where they play an essential role in immune surveillance. However, the accumulation of immature cells associated with decreased number of circulating DC Almand et al. 2000 Almand et al. , 2001 ) has deleterious effects for tumor surveillance. In patients with head and neck carcinoma, immature cells play a role in suppression of T-cell responses to recall antigens (Pak et al. 1995) and elevated tumor infiltration with immature cells correlated with increased rate of recurrence and metastases . Immature cells have the capacity to inhibit MHC-I as well as MHC-II restricted T-cell responses (Almand et al. 2001) . Although the mechanism of suppression has not been elucidated, a strict cell-to-cell contact with T cells is required to exert their suppressive activity (Almand et al. 2001) . In mice, 
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immature cells obtained from tumor-bearing hosts have been reported to express higher levels of reactive oxygen species (ROS) and accumulation of H 2 O 2 and arginase activity appeared to contribute. Inhibition of ROS abrogated the inhibitory effect, indicating that immature cells suppressed T-cell responses via production of ROS (Kusmartsev et al. 2004) . These data suggest that short-range immune mediators (i.e., ROS, H 2 O 2 or arginase) probably present lymphoid organs or at the tumor site on immature cells could play a crucial role in T-cell suppression. Accumulation of immature cells displacing competent APC populations (i.e., DC) could also account for immune suppression. We have reported that in patients with solid tumors immature DC represent a significant proportion (up to 65%) of the circulating DC compartment, thus impairing immune activation (Pinzon-Charry et al. 2005) . Interestingly and supporting a role for tumor products, a close correlation between accumulation of immature cells and tumor burden was evident. It is also tempting to speculate that while the systemic accumulation of immature cells could facilitate generalized immune dysfunction as a late event, immature APC present at the tumor site or lymphoid organs could play a role at an earlier phase in tumor progression. In fact, in patients with head and neck squamous cell carcinoma, tumor infiltration with immature cells has been correlated with increased rate of recurrence and metastases Tumors may also interfere with DC maturation, the final differentiation step whereby DC specialized in antigen capture are transformed into DC specialized in stimulation of T cells. Immature DC fail to provide an appropriate costimulatory signal to T cells and tolerance or anergy may develop. Indeed, antigen presentation by immature DC has been reported to result in induction of tolerance through abortive proliferation or anergy of antigen-specific T cells in vivo (Probst et al. 2003) . Immature DC can also induce tolerance through the generation of regulatory T cells that suppress immune responses by producing IL-10 and TGF- (Dhodapkar et al. 2001) . Immature DC with deficient expression of costimulatory molecules and poor capacity to stimulate T-cell responses have been reported in patients with basal cell, colorectal and breast cancer (Chaux et al. 1996; Gabrilovich et al. 1997) and DC from melanoma patients have an immature phenotype, reduced T-cell stimulatory capacity and induce anergy in syngeneic CD4 + T cells in vitro (Enk et al. 1997) .
DC-expressing indoleamine 2,3-dioxygenase (IDO) inhibit T-cell proliferation and promotes T-cell death as a result of prostaglandin induction (Braun et al. 2005) . Notably, large numbers of IDO-expressing DC can be found in tumor-draining lymph nodes, suggesting that they may be involved in the immunological unresponsiveness seen in cancer patients (Munn et al. 2002) . Therefore, it is tempting to speculate that similar mechanisms for induction of anergy occur in vivo at certain stages of tumor growth, an issue dealt in detail in a recent review (Munn and Mellor 2007) .
Tumor-Derived Factors and Dendritic Cell Apoptosis
Additional studies revealing other mechanisms utilized by tumors to evade effective immune responses have also been described. Induction of programmed cell death impairing the function of the key elements of the immune response like DC is one of such mechanisms. It has been demonstrated that DC undergo SPB- Her/2neu Hiltbold et al. (2000) U N C O R R E C T E D P R O O F apoptosis in vitro and in vivo after interacting with cancer cells or tumor-derived factors (Esche et al. 1999; Pirtskhalaishvili et al. 2000a,b; Balkir et al. 2004) confirming that malignancies use this mechanism to impair the generation of appropriate immune responses. Indeed, tumor cells are known to express or release numerous pro-apoptotic factors such as IL-10, nitric oxide, gangliosides or ceramides that induce DC to undergo apoptosis and may explain why T cells fail
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to become fully activated to eradicate adjacent tumor cells (Table 7 .1). Apoptotic DC are ineffective at inducing immunity. It has been demonstrated that DC undergoing apoptosis deliver unusual activation during antigen presentation, leading to cellular unresponsiveness rather than effective immunity (Kitajima et al. 1996) . Similarly, pre-apoptotic DC loaded with antigens show a marked decrease in their ability to induce antigen-specific immune responses in vivo (Colino et al. 2002) . In breast cancer, significant apoptosis of blood DC has been reported (Pinzon-Charry et al. 2005) . Circulating DC are essential for adequate immunity given that they continually replenish the pool of tissue-residing DC and play a critical role in shaping immune responses in vivo. Most circulating DC appear to be en route from the bone marrow to peripheral and lymphoid tissues or from non-lymphoid tissues to the regional lymph nodes and spleen (de la Rosa et al. 2003; Villadangos and Heath 2005) . Given that apoptotic cells are rapidly cleared from the circulation, the observation of a higher fraction of blood DC undergoing apoptosis in patients with breast cancer suggests increased turnover of these cells in vivo. Thus, continual efforts to replace the pool of blood DC from bone marrow would impose chronic stress on the immune system of breast cancer patients resulting in (i) relative paucity of DC in the circulation (Lissoni et al. 1999; Coventry et al. 2002) as well as (ii) failure to effectively replenish DC that infiltrate breast tumor tissue (Bell et al. 1999; Satthaporn et al. 2004) or (iii) migrate to lymphoid organs (Gabrilovich et al. 1997) for the initiation of T-cell immunity. Accordingly, in patients with operable breast carcinoma blood DC numbers are significantly reduced over prolonged periods of time suggesting diminished availability of DC precursors in cancer (Pinzon-Charry et al. 2007 ) .
Concluding Remarks
Overall, the evidence presented here emphasize the importance of DC in the elicitation of effective antitumor responses as well as the tumor-induced DC defects as a mechanism to escape immune surveillance. Tumors have been demonstrated to release numerous immunosuppressive factors that exert systemic effects on immune cell function and in particular, affect DC. The resulting dysfunction or apoptosis of mature DC, accumulation of immature DC or other immature cells with inhibitory functions would result in a significant deficiency in the induction of antitumor responses. The data examined also suggest that tumor-induced DC dysfunction represents one of the crucial mechanisms underlying tumor immune evasion and indicates that tumor-induced suppression
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of DC has to be avoided if attempts to improve immune response in cancer are sought.
There is active interest in using DC and exploiting their distinctive immune functions as vectors for immune therapy of cancer. Nevertheless, given the heterogenous nature of DC dysfunction in cancer, multiple strategies would have to be considered. One approach could be the induction of differentiation or optimization of immature DC or immature cell function with differentiation agents or growth factors in vivo (Garrity et al. 1997; Almand et al. 2001) . Another strategy would be the blockade of tumor-released factors that impair differentiation/function of DC in vivo (Gabrilovich et al. 1999 ). Finally, treatment of DC preparations (vaccines) with factors that increase their survival or resistance to apoptosis would be beneficial in the generation of antitumor immunity (Pinzon-Charry et al. 2006) . Clear understanding of DC-related tumor evasion mechanisms will harness the potential utilization of DC as natural adjuvants in immunological therapy and assist the development of new methods to overcome the ineffective immunity against cancer (Lopez and Hart 2002) .
